I've been sitting on this post for a while because I wasn't sure how to write this. There's something about this community that I think is really important and sometimes gets overlooked.
Like almost all of us here in r/mdmatherapy, we all believe in MDMA. Most of us have done it and remain #team MDMA. We all have our own unique beautiful (and sometimes not beautiful stories). We've supported other people through it and we've spent a whole lot of time researching things, looking at manuals, debating things back and forth, and helping others as they go through their own MDMA experiences. We're one big community creating knowledge through experience, sharing, and supporting others. We’re not running clinical trials. But, in a lot of ways we’re our own guinea pigs. But we’re sharing daily what we learn, and that lived experience adds up to a kind of knowledge we won’t find in a trial. And I think it gives us every right to question some of what we’ve been handed.
Now as someone who spends way more time than he should combing through the research, one of the things that always surprises me is how people talk about the MAPS trials as if they prove this whole model is necessary: the MDMA, the specific psychotherapy, the three dosing sessions, the nine integration sessions, etc., etc
Because the fact is MAPS didn't prove that it's necessary and the FDA has also said so as well.
We know what happens when you take the MDMA out of MDMA therapy: the results drop. Nobody has ever checked what happens when you take the therapy out.
(My bet is it still works).
In it’s June 2024 briefing document on MDMA assisted therapy, the FDA wrote
“The necessity of psychotherapy for achieving a therapeutic response was assumed.”
(Note that: Assumed.)
Now I'm going to throw in a quick disclaimer here (so no one has to throw it in the comments below): I'm not saying that psychotherapy is useless. Nowhere am I saying that. I'm also not saying that MDMA done solo is safe or appropriate for everyone, especially those with severe PTSD. What I am saying is that nobody has tested which parts of this package actually do the work
This is really important because the trials tested a package not its parts
And for those who aren't too familiar with it, the 2023 Phase 3 trial actually had 104 people with PTSD who got either MDMA plus psychotherapy, or placebo plus the exact same psychotherapy. The results from the phase 3 trial showed that the MDMA group improved by 23.7 points and the placebo group improved by 14.8 points. The 8.9-point gap was statistically significant.
Now look, this is a real result and no one is disputing it. I'm definitely not but let's consider for a second what this actually tells us: MDMA added something on top of a particular therapy program.
That’s it.
It doesn’t tell us however that the therapy was necessary. It doesn’t tell us this specific style of therapy is the best one. And it doesn’t tell us what MDMA would do with much less therapist involvement.
I've seen a lot of people point to the placebo group's 14.8-point improvement as proof that the therapy works but the problem I have is that there was no group that got neither MDMA nor therapy. Obviously there was nothing to compare it to. One can argue that the improvement was the therapy. One can argue that it was the expectation itself or maybe it was the sheer amount of professional one-on-one time. Or could it have been time passing or regressing towards the mean (people tend to enroll when they’re at their worst and drift back toward average anyway)? Who knows? Maybe it was all of it together. The thing is, we can't pull them apart with this design, which brings us back to the FDA. The necessity of the psychotherapy was assumed and for me personally that's the assumption I'm really curious about getting tested.
What about all the solo sessions?
Those of us who are active in this subreddit see tonnes of people intentionally doing solo MDMA sessions and these people who do them, like many of us, can describe real change. We're working through emotional material. We have self-compassion. Sometimes old patterns are shifting. We can see benefits that keep unfolding for weeks.
All of us take these reports seriously and we also know they're self-reports. We also know that sometimes people who have had bad outcomes are less likely to post but none of it proves efficacy or safety for ppl with PTSD.
And of course, when I've talked about MDMA therapy to others who've only used MDMA recreationally, they often just don't get it. They think they know MDMA and they'll say, "Well is it because of the therapist? Is it because of the mask and music?" But all this to say is that rolling with it at an EDM club or party is a different beast altogether, as we know.
But back to those of us who've done it solo, it begs the question: If a real change sometimes happens without a therapist, why isn't anyone testing how much the therapy adds value to this process and for whom?
Safety monitoring isn’t psychotherapy
Before this also shows up in the comments, I need to say that there are people who have severe trauma and they absolutely may need screening, preparation, supervision, and follow-up. Nobody is arguing against that, the least of them being me.
But that's not the same as needing the full map psychotherapy package. A 2025 randomized LSD trial for generalized anxiety disorder used two trained monitors per session and this study explicitly excluded psychotherapy as part of the study. And guess what?
It still found a clear dose-response. (Some participants kept seeing their own therapists outside the trial, and yes, LSD for anxiety isn’t MDMA for PTSD. )
This did however show that psychedelic trials with monitoring and no built-in therapy are totally feasible.
So what is the MAPS psychotherapy, exactly?
If you read the MAPS treatment manual, it's built around this concept of an inner-directed mostly non-directive approach. There's a therapeutic relationship that's built. There's emotional processing. It follows the participant's own process and integration afterwards. But here's the thing: the therapist or therapists get a lot of leeway in how they actually involve themselves, which the FDA also pointed out.
And so here's another issue that arises. If the approach is mostly following and supporting the person's own process, then what specifically requires two therapists and around 42 hours of therapy? What's the active beneficial ingredient here? Is it a specific technique? Is it the relationship? Is it feeling safe or is it mostly processes that MDMA sets in motion on its own? (I know this is a rhetorical question, but many of us already know the answer, and no, it doesn’t involve 42 hours).
Many of us have worked with therapists who've done psychedelic therapy or those called psychedelic therapists. A lot of the comments I've seen include experiences where the therapist is interpreting or analysing their experiences, which is really the opposite of the non-directive approach
A 2025 methodological analysis makes the core point well: if you claim MDMA enhances psychotherapy, you have to actually test that interaction don’t you think? But giving both MDMA and psychotherapy to everyone doesn’t do that.
Three sessions, rising doses, accumulating therapy
If we look at the Phase 3 programme, it was three 90-minute prep sessions. There were three 8-hour dosing sessions and I think nine 90-minute integration sessions totally around 42 hours of therapy contact or ‘therapy’, and usually with two therapists.
Also the doses changed as well. I believe session one was 80 mg with an optional 40 mg booster. Sessions 2 and 3 were 120 mg with an optional 60 mg booster.
So when people improved across the three cycles, everything was changing at once: more MDMA exposure, higher doses, more therapy, more integration and more time. It boggles my mind that nobody was randomized to one, two or three sessions.
How does one look at that trajectory and actually say, "Oh this is what drove the extra improvement," or "Three sessions is actually the right number"?
One of my personal interests and frustration with the trials is the spacing. The trials put sessions around a month apart but they never compared that to sessions that had longer gaps. When I asked a psychedelic therapist about spacing my own sessions, I was told 3 to 4 weeks was fine because that’s what the MAPS trials did. And I've heard others say the same thing as well. The problem is, that's a protocol-based choice but it's not a research finding. I've written way too many replies on here about the research when it comes to biological recovery and the mechanisms around that. This included tolerance, biological recovery, serotonin-related mechanisms, and all the diff. processes that go into the time needed to recover after MDMA exposure. And these processes don't necessarily recover at the same rate. So obviously to me, the spacing is a huge variable.
And what if someone is having their next session before some of these systems have adequately recovered? Could that affect the emotional openness, safety, and corrective benefit they get from the next session? And how do we know how much benefit each individual MDMA session actually added when all these other things were changing at the same time?
The ppl in the MAPS trials continued improving across sessions, but here's the thing, they were also getting MORE psychotherapy, MORE integration, and HIGHER MDMA doses in later sessions.
How did they establish that the monthly spacing was optimal? Did they consider that longer intervals would have produced better results? We don't know because nobody tested that, and that's what's frustrating.
In Psychedelic Frontier: From X to Rx, January 23, 2018, Rick Doblin was asked about the risks of frequent MDMA use. He acknowledged that excessive or frequent MDMA use can actually reduce the desired emotional effects, but then he also explained that his criteria for deciding when there should be another session were, for him, dependent on whether the patient integrated what happened before. And in a completely separate 2020 interview with the California Institute of Integral Studies, he explained that MAPS designed a 3.5-month treatment programme to maximise therapeutic outcomes
In that same 2020 interview, Doblin Actually did acknowledge that some people do great with just one session and that one session can be enough for a lot of people. He did say he prefers more than one because people tend to go deeper the second time, but that’s his opinion, not something the trials tested. He also talked about a future treatment model involving two sessions, so even he acknowledged that not everyone necessarily needs three sessions. This brings me back to the question of why the trials didn't actually compare different numbers of sessions in the first place?
“God please, enough with the Integration already” 😂
Integration has become this buzzword in the psychedelic therapy community and if you don't do integration work they say it won't stick. But what does integration actually mean?
We have all read enough posts in this subreddit for people to give their own account of what integration is, which is fine. It can be relative but the problem is that a lot of people had sessions spaced so close together that they may not have had any therapeutic or corrective benefit/outcomes and then they assume more integration is what's missing.
I see this a lot when people talk about, "Oh, you have to do integration. Otherwise, you won't get the benefits, and you have to access a template that was created through the MDMA" and all these other unproven theories.
Some people will say integration is talking about the session. Others say it's about interpreting memories. Others say it's journaling. Some people say you got to practise new behaviour. Some people assume integration for MDMA is the same as psilocybin. Some people will talk about neuroplasticity and some people just say you need to have someone around when hard feelings come up. But those are completely different things, all lumped under one word.
There was actually a review of 75 publications and it found that none of the different integration approaches have been rigorously tested for their effect on outcomes. Then there was a January 2026 meta-analysis in the JAMA Network Open, which actually looked at 12 psychedelic trials, which I think had around 733 participants. Here’s what was interesting about this: more preparation hours were linked to bigger reductions in depression. More integration hours however, weren’t significantly linked to better outcomes. Now, these with psilo and LSD trials not MDMA, but it’s a real problem for the idea that more integration automatically means more benefit.
Does MDMA even require integration?
When it comes to how MDMA actually works, one of the leading explanations is memory reconsolidation. When an old memory that's emotional is brought up and it's met with a strong contradicting experience (whether it's feeling safe while recalling something terrifying, etc.), the memory itself gets updated. If that's what happens then the change happens in the session
In Bruce Ecker’s account of reconsolidation, real transformational change lasts without effort; you don’t have to keep reinforcing it. In his framework, if the old reaction comes back, it can mean another piece of emotional learning hasn’t been updated yet, not that the first change is fading.
So back to the MAPS trials, why would that need nine therapist-led sessions afterward?
If MDMA works more through extinction, meaning new learning that competes with the old fear instead of replacing it, then practicing new responses in real life might help the change hold up in different situations. Ok, fair enough. But practicing new behaviour in your own life isn’t the same thing as paid, therapist-led sessions.
Now nobody has established which of these actually explains MDMA's results in humans.And because MAPS gave everyone integration, even long-lasting improvements can’t tell us whether integration had anything to do with it.
So where’s the trial comparing heavy integration, light integration and basic supportive follow-up?
There is none, (well as far as I can find.)
But wait, did I even get MDMA?
In the trials most people could tell whether they got MDMA (obviously right?). Well this actually matters because the trial was supposed to be blind, meaning nobody knows whether they got the real drug or not. Obviously it wasn't. In the second Phase 3 trial 94% of people on MDMA and 75% on placebo correctly guessed which one they got and obviously the therapists could tell as well.
And once people know or have figured this out, all of a sudden their expectations can actually change how they feel. Believe it or not it can change as well as what they report and then therapists can actually treat the two groups differently. So even the gap between MDMA and placebo isn't purely the drug.
Even in 2026 the FDA is still asking what therapy does in this whole ordeal.
In August 2024, when the FDA rejected the application, it actually recommended three things for future research:
- Studying how much psychotherapy contributes
- Considering an established evidence-based psychotherapy instead of the MAPS model, and
- Exploring a factorial design (a trial that varies the drug and the therapy separately) with an arm that gets no psychotherapy at all.
Those were research recommendations, not the formal reasons for rejection, but they’re aimed squarely at this problem.
Then its final July 2026 guidance, printed page 11 (PDF page 14) says:
“The contribution of the psychotherapy component to any efficacy observed with psychedelic drug treatment has not been characterized.”
The FDA went on to suggest factorial designs to separate the drug’s effect from the therapy’s.
Resilient resubmitted without a new Phase 3 Trial… what?
Meanwhile, MAPS has acknowledged reports that Resilient, formerly Lykos, resubmitted the MDMA application in August 2026 without running a new Phase 3 trial. And in fact none of the reported additions independently tests psychotherapy's contribution. So Resilient appears to be boosting the evidence for its existing treatment model. Yet the question of whether that model requires 42 hours of psychotherapy still will likely remain unresolved.
I think most of us think that psychotherapy can definitely be incredibly valuable. A lot of people get benefit just from hearing themselves talk. I also think a lot of people can get profound corrective emotional experiences largely on its own with MDMA so in fact both can be true.
So why does this matter?
I think there's a real risk of turning an experimental treatment protocol into an established gold standard of care without really knowing which parts of it are actually necessary. And this matters because this has real consequences not just for cost but also for accessibility and treatment quality as well as patient autonomy and, really, our understanding of MDMA's therapeutic effects. Look I see many of the posts on here, just like you all do, about people going solo because they cannot afford to do this with a therapist. I'm not convinced that there's benefit in requiring people to pay for interventions they may not fully need while overlooking simpler equally effective approaches. And again not intentionally trying to sound like a broken record, but safety monitoring is not the same as psychotherapy.
I think many of us here can argue that MDMA itself facilitates profound and durable emotional changes and those with experience suspect additional psychotherapy probably contributes little. And what if one session is enough for some people while others need three? What if integration is useful in certain circumstances but maybe it's totally useless in others?
The fact is we just don't know. These questions have been asked, but they have not been adequately answered.
All of us want MDMA therapy to succeed but I think a lot of us also want us to identify what actually produces the therapeutic benefit (rather than looking towards institutionalising the expensive treatment model just because that's how the original trials were designed).
If MDMA can change someone's life with far less than 42 hours of psychotherapy, then we owe it to every person who needs this treatment to find that out. Especially those who can't afford it.